Effect of 14-day Repeated Oral Doses of SAR302503 on Ventricular Repolarization, Compared to 1-day Placebo in Adult Patients With Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2014
At a glance
- Drugs Fedratinib (Primary) ; Palonosetron
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors Sanofi
- 21 Nov 2013 Planned End Date changed from 1 Apr 2014 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 18 Nov 2013 Status changed from recruiting to discontinued, according to a Sanofi media release. Development of fedratinib has been discontinued.
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.